Compare SINT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | CALC |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 9.7M |
| IPO Year | 2007 | 2020 |
| Metric | SINT | CALC |
|---|---|---|
| Price | $2.45 | $0.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $11.00 | $10.00 |
| AVG Volume (30 Days) | 29.8K | ★ 184.3K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,018,000.00 | N/A |
| Revenue This Year | $30.26 | N/A |
| Revenue Next Year | $413.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.46 |
| 52 Week High | $6.78 | $7.20 |
| Indicator | SINT | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 42.90 |
| Support Level | $2.30 | $0.50 |
| Resistance Level | $2.97 | $0.78 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 50.99 | 47.36 |
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.